FERRING-PHARMACEUTICALS
9.4.2024 07:16:34 CEST | Business Wire | Press release
Ferring today published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates (AER), but an increase of +1% at constant exchange rates (CER). EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million.
The year marked a major turning-point for Ferring with the launch of two innovative first-in-class medicines in the United States. Rebyota® (fecal microbiota, live – jslm) is the first microbiome-based live therapeutic ever approved by the US Food and Drug Administration, while Adstiladrin® (nadofaragene firadenovec-vncg) represents a new form of gene therapy with the potential to transform the treatment of certain urological cancers. The commercial potential of Adstiladrin was recognised by a US$500 million royalty financing agreement with Royalty Pharma, a leading funder of innovation in the biopharmaceutical sector.
Ferring is evolving to make the most of these opportunities, and there were a number of significant changes to the senior leadership. In July 2023, Jean-Frédéric Paulsen became Chairman of the company founded by his grandfather Dr. Frederik Paulsen and Eva Paulsen in 1950. Lars Rebien Sørensen, who has held the post of Chairman since 2021, remains on the Board as Vice-Chairman, ensuring continuity of leadership. Jeffrey Hobbs stood down as Vice Chairman and Executive Director following several decades of outstanding contribution to the Ferring Group. Hélène Ploix and Alexandra, Countess of Frederiksborg, also stood down from the Board of Directors after many years of invaluable service.
Two new members joined the Board of Directors – Viviane Monges, who took over as Chair of the Audit and Finance Committee, and Henrik Normann, member of the Board of Directors, who was previously President and CEO of Nordic Investment Bank. In April 2024, Per Falk stood down as President, a position he held since 2019. Ferring’s Executive Committee was strengthened by the appointment in January 2023 of Pierre-Yves Berclaz as Chief Medical Officer, and in January 2024 Cyril Grandchamp-Desraux as Chief Commercial Officer.
Jean-Frédéric Paulsen, Chairman of the Board of Directors, said: “The launch of two groundbreaking medicines in the US, along with the other important changes in 2023, mark the start of an exciting new phase of growth for Ferring. As we look forward to another year filled with enormous potential, I am confident in the qualities of our senior executive team and the thousands of colleagues worldwide whose dedication and expertise will help to ensure that we succeed in our mission of building families and helping people live better lives.”
Ferring has also maintained its environmental, social and governance (ESG) progress and, in 2023, embarked on a programme to embed sustainability into its activities worldwide. In a major milestone, we marked the tenth anniversary of #ProjectFamily Safe Birth, a public-private partnership which aims to address postpartum haemorrhage (PPH), the leading cause of maternal mortality worldwide.1 In 2023, we provided one million doses of Carbetocin Ferring, our heat-stable medicine for the prevention of PPH, at a not-for-profit, affordable price to public and not-for-profit health facilities in low and lower-middle income countries. Ferring’s contribution was recognised with inclusion in Fortune’s ‘Change the World’ List of companies that have had the greatest impact in addressing society’s unmet needs.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X (Twitter).
______________________________
1 World Health Organization. A Roadmap to Combat Postpartum Haemorrhage between 2023 and 2030. 2023. Available at https://cdn.who.int/media/docs/default-source/reproductive-health/maternal-health/pph-roadmap.pdf?sfvrsn=db36b511_3 Accessed April 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408912190/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euroAtlantic Airways Expands Long-Haul Fleet With a New Airbus A330-300 Aircraft2.9.2026 09:00:00 CEST | Press release
euroAtlantic Airways (“EAA”), a Njord Partners portfolio company and a leading Portuguese aircraft wet-leasing and charter business, is pleased to announce the induction of a new Airbus A330-300 aircraft into its fleet, further strengthening its long-haul widebody capabilities and reinforcing the Company's growth trajectory in the ACMI and charter markets. The Airbus A330-300 is leased from Jackson Square Aviation (JSA). Only 15 years old, the aircraft is configured in a three-class layout of Business, Premium Economy and Economy, accommodating a total of 290 passengers, and features full lie-flat seating in Business Class along with personal in-seat entertainment monitors fitted across the entire cabin. The aircraft, which will be registered as CS-TGI after completing its normal process of approval with authorities, has already completed its delivery journey, departing Kuala Lumpur (KUL) and arriving into Beja, Portugal (BYJ) on 17 August 2026. This aircraft type is known for its effi
Interoperability and Trust Key to AI Commerce: Alipay+ and S&P Global Report2.9.2026 08:33:00 CEST | Press release
Report shows consumers expect mobile wallets to evolve beyond payments into integrated platforms for travel, rewards, commerce and AI-powered servicesCross-border payments remain fragmented with more than half of consumers lacking access to preferred payment and facing uncertainty over payment acceptance AI adoption is accelerating across discovery and planning, but 43% express privacy concerns, and strengthening trust needed to scale AI-enabled commerce A new report by Alipay+, the unified wallet gateway of Ant International, in partnership with S&P Global, reveals a growing "commerce digitalisation gap", with people increasingly expecting seamless mobile payments and intelligent digital assistance, yet friction – from inconsistent payment acceptance to trust in AI – still define their experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901394299/en/ The study, which surveyed 6,000 consumers across nine markets in
Axelspace Announces Partnership with Airbus Defence and Space to Deliver Satellite Imagery to a Broader Market2.9.2026 08:30:00 CEST | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” announced today a new agreement with Airbus Defence and Space, a global leader in Earth observation including optical and radar satellite imagery, to provide mid-resolution optical images captured by Axelspace’s Earth observation microsatellites “GRUS.” Under this strategic partnership, we will develop and deliver innovative solutions that meet long-term customer needs for utilizing satellite imagery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901360086/en/ GRUS is Axelspace's series of approximately 100 kg-class optical Earth observation microsatellites. GRUS-1 is currently operated as a four-satellite constellation, delivering high-frequency, wide-area imagery. This imagery, together with value-added solutions derived through processing and analysis, supports a broad range of industries, including agr
Kontoor Brands Unveils Helly Hansen Growth Strategy and 2030 Financial Targets2.9.2026 08:30:00 CEST | Press release
Kontoor Brands, Inc. (NYSE: KTB) today announced Helly Hansen’s long-term growth strategy and 2030 financial targets, which Kontoor Brands will present at the Helly Hansen® Investor Day later today. The plan is designed to scale Helly Hansen globally while significantly expanding its profitability through 2030. "With 150 years of technical heritage and an authentic right to win globally, Helly Hansen is a brand with tremendous long-term growth potential," said Scott Baxter, Chief Executive Officer and Chairman of the Board of Kontoor Brands. "Strong alignment between our teams has allowed us to integrate quickly and move straight to executing against the opportunity ahead. Our sustained investment in Helly Hansen will be a catalyst for its next phase of growth, and we are confident in our ability to deliver significant value for our consumers, employees and shareholders for years to come." A Focused Growth Strategy: To deliver against these targets, Helly Hansen’s growth is anchored in
Vara Receives World-First CE Certification for Autonomous AI in Breast Cancer Screening2.9.2026 08:00:00 CEST | Press release
Vara has received CE certification under the EU Medical Device Regulation (Class IIb) for autonomous triage in organised breast cancer screening – the first breast AI certified anywhere to report screening examinations as normal without radiologist review. In autonomous triage, examinations the system classifies as clearly normal can be reported by AI without a radiologist reading them; every other examination continues to be read by at least one radiologist. This deployment mode is intended for organised population screening, where a shrinking radiologist workforce is straining programmes that still read every mammogram twice. The certification has only been possible because Vara has developed a safety system that supervises the autonomous use of its AI models. "What made this possible is not the AI model alone," said Stefan Bunk, CTO and co-founder of Vara. "It is based on seven years of continuous monitoring of how our AI performs in the real world, on every single case. That experi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom